Abstract
Melanoma immunotherapy is still not satisfactory due to immunosuppressive cell populations within the tumor stroma. Targeting tumor-associated macrophages (TAM) can help to restore an anti-tumor immunity. Previously, we could show that classical TAM markers expressed in vivo need a 7 day M-CSF/dexamethasone/IL-4 (MDI) stimulation for their induction in peripheral blood monocytes (pBM) in vitro. To identify possible novel therapeutic targets on TAM, gene expression analysis of MDI-treated pBM was performed. This identified up-regulation of the purinergic G-protein coupled receptor P2Y12, the therapeutic target of the clinically approved anti-thrombotic drugs cangrelor, clopidogrel, ticagrelor, and prasugrel. We generated a peptide antibody and validated its specificity using transgenic P2Y12+ U937 cells. With the help of this antibody, P2Y12 expression was confirmed on CD68+ CD163+ TAM of melanoma in situ. Functional analysis revealed that treatment of transgenic P2Y12+ U937 cells with the receptor agonist 2-MeSADP induced ERK1/2 and Akt phosphorylation and increased the secretion of the chemokines CXCL2, CXCL7, and CXCL8. These effects could be abolished with the P2Y12 antagonist PSB0739 or with Akt and ERK inhibitors. In addition, P2Y12+ macrophages migrated towards the ADP-rich culture medium of puromycin-treated dying B16F1 melanoma cells. Cangrelor treatment blocked migration. Taken together, our results indicate that P2Y12 is an important chemotaxis receptor, which triggers migration of macrophages towards nucleotide-rich, necrotic tumor areas, and modulates the inflammatory environment upon ADP binding.
Highlights
Immunosuppressive cells such as tumor-associated macrophages (TAM) are prominent components of the tumor microenvironment[1]
We demonstrate that adenosine diphosphate (ADP) acts as a find-me signal as nucleotides released by dying tumor cells significantly promote the migration of P2Y12+ macrophages
Since it is known that P2Y12 triggers migration of microglia cells to the site of inflammation, we investigated whether ADP might act as a chemoattractant for other P2Y12+ macrophages
Summary
Immunosuppressive cells such as tumor-associated macrophages (TAM) are prominent components of the tumor microenvironment[1]. A high infiltration of TAM correlates with poor outcome in different tumor entities including melanoma[2]. Macrophages are highly plastic cells that quickly adapt to different environments[3]. Based on Official journal of the Cell Death Differentiation Association. Kloss et al Cell Death and Disease (2019)10:760. Microenvironment[7,8]. Based on the described pro-tumoral and immunosuppressive abilities of M2-like macrophages they classify as promising therapeutic targets especially when combined with immune checkpoint inhibitors[9]. It is crucial to identify and characterize novel TAM markers that can be targeted therapeutically to improve an anti-melanoma immune response
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
